Roth Capital Estimates GeoVax Labs FY2029 Earnings

GeoVax Labs, Inc. (NASDAQ:GOVX) – Roth Capital issued their FY2029 EPS estimates for shares of GeoVax Labs in a report released on Friday, March 28th. Roth Capital analyst J. Aschoff forecasts that the company will earn $12.20 per share for the year. The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share.

Separately, D. Boral Capital restated a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research report on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.20.

GeoVax Labs Price Performance

NASDAQ:GOVX opened at $1.08 on Monday. The company has a market cap of $10.19 million, a price-to-earnings ratio of -0.19 and a beta of 3.06. GeoVax Labs has a 1 year low of $1.03 and a 1 year high of $11.18. The stock’s 50 day simple moving average is $1.62 and its two-hundred day simple moving average is $2.10.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The firm had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million.

Institutional Investors Weigh In On GeoVax Labs

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp purchased a new position in shares of GeoVax Labs in the 4th quarter worth approximately $29,000. Virtu Financial LLC purchased a new position in GeoVax Labs during the third quarter worth $97,000. Citadel Advisors LLC bought a new position in GeoVax Labs during the fourth quarter valued at $104,000. Finally, Geode Capital Management LLC raised its stake in shares of GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares during the period. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.